"Sangamo BioSciences (NASDAQ: SGMO) has again received significant scientific validation for its proprietary technology," says biotech expert John McCamant.
In The Medical Technology Stock Letter, he explains, ""Part of what has gotten investors so excited about stem cells was the concept that some day scientists would be able to create 'personalized' stem cell types for individual therapy. We believe that this is the break that was needed to realize the potential of stem cell therapy."
"Stem cells differ from other cell types in two fundamental ways. First, they are unspecialized cells capable of renewing themselves through cell division.
"Second, under certain conditions, they can be induced to become tissue- or organ-specific cells with special functions.
.gif){kind=logo}
Why isn't Bank of America updating its shareholders on CEO situation?
Before the bell: Futures sharply lower on Dubai's debt problems
Will Rich Ross really have a positive impact on Disney's movie operations?
